PRODUCT INFORMATION

Flecainide BNM

Tablets 50 mg & 100 mg

NAME OF THE MEDICINE

Non-proprietary name: Flecainide acetate
Chemical structure:

```
C17H20F6N2O3.C2H4O2
```

Molecular formula: C_{17}H_{20}F_{6}N_{2}O_{3}.C_{2}H_{4}O_{2}
Molecular weight: 474.4
CAS no: 54143-56-5

DESCRIPTION

Flecainide acetate; N-(2-piperidinylmethyl)-2, 5-bis (2,2,2-trifluoroethoxy) benzamide acetate, belongs to the benzamide class of antiarrhythmic drugs and is structurally related to lignocaine and procainamide. It is chemically distinguished from these agents by the presence of trifluoroethoxy- substituents in the aromatic portion of the molecule and a piperidine ring in the amide side chain instead of the diethylaminoethyl group of the procainamide side chain. The compound is a racemic mixture. It is soluble in water, dilute acetic acid, methanol and ethanol and practically insoluble in dilute hydrochloric acid. The pKa of flecainide acetate is 9.3.

Excipients:
Pregelatinised maize starch, croscarmellose sodium, microcrystalline cellulose, maize starch and magnesium stearate.

PHARMACOLOGY

Pharmacology: Flecainide belongs generally to the membrane stabilising (Class 1) group of antiarrhythmic agents, however, it has its own characteristic electrophysiological effects. Its predominant effect on the transmembrane action potential in single cell preparations from canine Purkinje fibres is to decrease the rate of rise (V max, Phase 0) of the action potential without greatly affecting duration. In these same preparations, the duration of the effective refractory period was lengthened and little, if any, change was observed in the slope of Phase 4 depolarization. In ventricular muscle, some lengthening of the action potential duration has been observed. These results are consistent with the postulate that the predominant action of flecainide is to inhibit the fast, or sodium, channel which is largely responsible for the rapid upstroke of the myocardial action potential in cardiac conducting
tissue. No significant anticholinergic or α or β antadrenergic effects have been found in animal studies. Animal studies have also shown that flecainide possesses a significant degree of local anaesthetic activity.

**Electrophysiology:** Studies of the effects of flecainide on intracardiac conduction in man have shown that the drug depresses conduction in all parts of the heart with the greatest effect on the His-Purkinje system (H-V conduction). Smaller increases were noted in atrioventricular (AV) nodal conduction and in intra-atrial conduction times and effects on refractory periods were less pronounced than those on conduction velocity. Sinus node recovery times (corrected) following pacing and spontaneous cycle lengths were increased, but not significantly, in patients with normal sinus node function. Pronounced depression of sinus node function in patients with sinus node dysfunction has been reported. Significant prolongation of the PR interval, QRS duration and the QT interval (corrected) have been detected electrocardiographically in human studies, although the JT (QT - QRS) interval is not significantly affected. Flecainide is known to reversibly increase endocardial pacing thresholds.

**Haemodynamics:** Flecainide does not usually alter heart rate, although bradycardia and tachycardia have been reported infrequently. In clinical studies, mean systolic and diastolic blood pressures increased slightly and sometimes significantly during therapy. Single dose oral and intravenous studies have provided evidence for a slight negative inotropic effect for flecainide. Evidence for slightly but significantly decreased myocardial contractility with maintained pump function was detectable following administration of a single 250 mg oral dose to patients and healthy subjects using systolic time intervals as well as M-mode and two-dimensional echocardiography. Patients with chronic stable ventricular arrhythmias without significant pre-existing congestive failure have shown no changes in ejection fraction and other indices of contractility as determined by echocardiography after two weeks of treatment with therapeutic doses of flecainide. One study of patients with complex ventricular arrhythmias having a mean pre-flecainide ejection fraction of about 42% showed a slight but significant decrease to 38% in this parameter after short term treatment. Another study of patients with ventricular tachycardia and a mean pre-treatment ejection fraction of 22% showed no change in ejection fraction after 4-14 days of flecainide therapy (mean daily dose 242 mg).

**Pharmacokinetics:**

*Absorption*

The absorption of oral flecainide is reasonably prompt and nearly complete. Peak plasma drug levels are attained at about 3 hours in most individuals (range 1-6 hours). Therapeutic plasma levels of flecainide range from 0.2 to 1.0 µg/mL. Flecainide does not undergo any first pass effect. Food does not affect either the rate or extent of flecainide absorption. The mean plasma half-life in patients with premature ventricular contractions following multiple oral dosage is about 20 hours (range 12-27 hours).

*Distribution*

The volume of distribution ranges from 5 to 13.4 L/kg (mean 8.7 L/kg) indicating that the drug is widely distributed into the tissues. The extent of flecainide binding to human plasma proteins is about 40% and is independent of plasma drug level over the range 15-3,400 ng/mL.
**Metabolism**
In healthy subjects about 30% of a single oral dose (range 10-50%) is excreted in urine as unchanged drug. The two major urinary metabolites, meta-O-dealkylated flecainide and the meta-O-dealkylated lactam of flecainide in conjugated and unconjugated forms, account for most of the remaining portion of the dose. Metabolic degradation of flecainide appears to be genetically determined.

**Excretion**
Poor metabolisers have lower metabolic clearance of flecainide. However, since flecainide, to a large extent, is also excreted renally, it is unlikely that a reduced metabolic clearance in poor metabolisers is of any clinical consequence, except in patients with renal failure. For patients with moderate renal failure, the rate of flecainide elimination from plasma and the extent of unchanged drug excretion in urine are only somewhat less than for healthy subjects. In contrast, the extent of flecainide excretion in urine is markedly lower in patients with end-stage renal disease and the rate of elimination of flecainide from plasma is slower in some end-stage patients. For patients with congestive heart failure (NYHA Class III), the rate of flecainide elimination from plasma is about 25% slower than for healthy subjects, but the extent of unchanged drug excretion in urine is comparable. (See "Dosage and administration" for dosage in patients with renal disease or congestive heart failure.)

**INDICATIONS**
Flecainide BNM is indicated for:

1. Supraventricular arrhythmias:
   a) due to pre-excitation syndromes, e.g. Wolff-Parkinson-White and Lown-Ganong-Levine syndromes.
   b) due to dual AV nodal pathways in patients with debilitating symptoms.
   c) paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms.

Although flecainide may be effective in supraventricular arrhythmias in patients with structural heart disease, its use has been associated with life-threatening and occasionally fatal ventricular arrhythmias. In these patients, particularly in the presence of impaired left ventricular function, flecainide should be used with extreme caution, preferably after other antiarrhythmic drugs have been tried or considered inappropriate.

Use of flecainide in chronic atrial fibrillation has not been adequately studied and is not recommended.

2. Life threatening ventricular arrhythmias not controlled by other drugs.

Flecainide BNM tablets are used for continuous maintenance of normal rhythm following initial oral or intravenous therapy or conversion by other means.

Prescribers should also consult the "Precautions" section of this Product Information.
CONTRAINDICATIONS

- Second or third degree AV block, unless a pacemaker is present to sustain rhythm.
- Right bundle branch block when associated with a left hemi-block (bifascicular block) unless a pacemaker is present to sustain rhythm.
- Cardiogenic shock.
- Asymptomatic premature ventricular contractions and/or asymptomatic non-sustained ventricular tachycardia in patients with a history of myocardial infarction.
- Known hypersensitivity to the drug.
- In patients with severe renal or hepatic impairment unless plasma level monitoring can be done.

PRECAUTIONS

Mortality: In the Cardiac Arrhythmia Suppression Trial (CAST), a long-term, large scale, multi-centre, double-blind, randomised, placebo-controlled clinical trial in patients with asymptomatic non-life threatening ventricular arrhythmias who had myocardial infarction more than six days but less than two years previously, oral flecainide was associated with a higher incidence of mortality or non-fatal cardiac arrest (19/323) as compared with its matching placebo (7/318). The average duration of treatment with flecainide in this study was 10 months. In that same study, an even higher incidence of mortality was observed in flecainide-treated patients with more than one myocardial infarction. While there are no comparable mortality trial data for other Class I antiarrhythmic agents post myocardial infarction, meta-analysis of small scale clinical trials of these agents in similar populations suggests a trend towards increased mortality compared to placebo. In the light of this information, it is prudent to consider the prophylactic use of Class I antiarrhythmic drugs following myocardial infarction as potentially hazardous. Indeed, the use of these agents for other than life-threatening arrhythmias or severe symptoms due to arrhythmias, is not recommended. Comparable placebo-controlled clinical trials have not been done to determine if flecainide is associated with a higher risk of mortality in other patient groups.

Structural heart disease: Patients with structural heart disease, treated with flecainide for supraventricular arrhythmias, may be at increased risk for proarrhythmia and cardiac adverse events. The use of flecainide in these patients has been associated with life-threatening and occasionally fatal ventricular arrhythmias. Therefore, in these patients, especially in the presence of impaired left ventricular function with ejection fraction \( \leq 40\% \), Flecainide BNM should be used with extreme caution, preferably after other antiarrhythmic drugs have been tried or considered inappropriate.

Ventricular proarrhythmic effects in patients with atrial fibrillation/flutter: A review of the world literature revealed reports of 568 patients treated with oral flecainide tablets (flecainide acetate) for paroxysmal atrial fibrillation/flutter (PAF). Ventricular tachycardia was experienced in 0.4% (2/568) of these patients. Of 19 patients in the literature with chronic atrial fibrillation, 10.5% (2/19) experienced ventricular tachycardia or ventricular fibrillation. FLECAINIDE IS NOT RECOMMENDED FOR USE IN PATIENTS WITH CHRONIC ATRIAL FIBRILLATION. Case reports of ventricular proarrhythmic effects in
patients treated with flecainide for atrial fibrillation/flutter included increased premature ventricular contractions (PVCs), ventricular tachycardia (VT), ventricular fibrillation (VF) and death.

As with other Class I agents, patients treated with flecainide for atrial flutter have been reported with 1:1 atrioventricular conduction due to slowing of the atrial rate. A paradoxical increase in the ventricular rate also may occur in patients with atrial fibrillation who receive Flecainide BNM. Concomitant negative chronotropic therapy such as digoxin or β-blockers may lower the risk of this complication.

Proarrhythmic effects: As with other antiarrhythmic drugs flecainide has been associated with the development of new or worsened arrhythmias. These so-called proarrhythmic effects may range in severity from an increase in frequency of PVCs to the development of more severe forms of ventricular tachycardia. In a few patients flecainide has been associated with episodes of unresuscitated ventricular tachycardia or ventricular fibrillation. The incidence of proarrhythmic events was higher in studies of patients treated for recurrent ventricular tachycardia, often with coexisting congestive heart failure, than in studies of patients treated for stable ventricular ectopy. Treatment with any antiarrhythmic agent should be initiated in hospital in patients treated for recurrent sustained ventricular tachycardia, especially those with congestive heart failure or low ejection fractions. Effective use of Flecainide BNM may be assisted in some patients by electrophysiological investigation.

Heart failure: Because flecainide has a mild negative inotropic effect, it may cause or worsen congestive heart failure, particularly in patients with cardiomyopathy, pre-existing severe heart failure (NYHA functional Class III or IV) or ejection fractions ≤ 40%. Flecainide BNM should therefore be used cautiously in patients who are known to have a history of congestive heart failure or myocardial dysfunction. The initial dose should be no more than 100 mg b.d. (see "Dosage and administration") and they should be monitored carefully. Careful attention must be given to maintenance of cardiac function, including optimisation of digitalis, diuretic or other therapy. In the cases where congestive heart failure has occurred during flecainide therapy, the onset has ranged from a few hours to several months after starting therapy. Some patients who develop evidence of reduced myocardial function while on Flecainide BNM can continue on Flecainide BNM with adjustment of digitalis or diuretic, others may require dosage reduction or discontinuation of Flecainide BNM. When feasible, it is recommended that plasma flecainide levels be monitored. Attempts should be made to keep trough plasma levels below 0.7 to 1.0 µg/mL.

Effects on cardiac conduction: Flecainide slows cardiac conduction sufficiently in most patients to produce measurable increases in the duration of the PR, QRS and QT intervals on the electrocardiogram. This is an extension of the pharmacological action of the drug and most patients experience no detrimental clinical effects from these changes in conduction. Increases of more than 25% in the duration of the PR interval occur commonly and approximately one third of patients may develop first-degree heart block (PR interval greater than or equal to 0.20 seconds). Widening of the QRS of 25% or more is also common and many patients develop QRS complexes with a duration of 0.12 seconds or more. The QT (uncorrected) interval widens about 8% on the average, mostly due to the widening of the QRS. (The JT interval [QT minus QRS] is usually unaffected or widens about 4%).
Although clinically significant conduction changes such as sinus pause, sinus arrest, second or third degree AV block occasionally occur, an attempt should be made to reduce the dosage of Flecainide BNM (see "Dosage and administration") to the lowest effective dose in an effort to minimise these effects. If second or third-degree AV block, or right bundle branch block associated with a left hemi-block occur, Flecainide BNM therapy should be discontinued unless the ventricular rate is adequately controlled by a temporary or implanted ventricular pacemaker.

**Sick sinus syndrome (bradycardia-tachycardia syndrome):** Flecainide BNM should not be used in patients with advanced sinus node disease and should be used only with extreme caution in patients with sick sinus syndrome because it may cause sinus bradycardia, sinus pause, or sinus arrest. Pacing rescue facilities should be available.

**Digitalis intoxication:** Flecainide BNM has not been evaluated in the treatment of arrhythmias secondary to digitalis intoxication and it increases the plasma level of digoxin (see "Interactions with other medicines"), therefore it is not recommended for such use.

**Electrolyte disturbances:** The presence of a potassium excess or deficit may alter the effects of Class I antiarrhythmic drugs. Any pre-existing hypokalaemia or hyperkalaemia or other electrolyte disturbances should be corrected before administration of Flecainide BNM.

**Effects on pacemaker thresholds:** Flecainide is known to reversibly increase endocardial pacing thresholds and may suppress ventricular escape rhythms. It should be used with caution in all patients with permanent pacemakers or temporary pacing electrodes and should not be administered to patients with existing poor thresholds or non-programmable pacemakers unless suitable pacing rescue is available. It is suggested that the threshold in patients with pacemakers be determined prior to instituting therapy with Flecainide BNM, again after one week of administration and at regular intervals thereafter. Generally threshold changes are within the range of multiprogrammable pacemakers and when these changes occur, usually a doubling of either voltage or pulse width is sufficient to regain capture.

**Concomitant antiarrhythmic therapy:** Due to limited exposure, the concomitant use of Flecainide BNM and other antiarrhythmic agents is not recommended.

Both disopyramide and verapamil have negative inotropic properties and the effects of co-administration with flecainide are unknown. Neither disopyramide nor verapamil should be administered concurrently with Flecainide BNM, unless, in the judgement of the physician, the benefit of this combination outweighs the risks.

Formal interaction studies have not been conducted with amiodarone and flecainide. However, clinical experience indicates, as for many other antiarrhythmic agents, that amiodarone can increase plasma levels of flecainide. If in the judgement of the physician the benefits outweigh the risks and Flecainide BNM is to be administered in the presence of amiodarone, the dose of Flecainide BNM should be reduced (see "Dosage and administration") with plasma flecainide monitoring.
Lidocaine has been used occasionally with flecainide while awaiting the therapeutic effect of flecainide. No adverse drug interactions were apparent. However, no studies have been performed to demonstrate the usefulness of this regimen.

**Alkaline urine:** In the presence of alkaline urine (pH greater than 7.0) which may result from diet, concomitant medication or disease states, flecainide elimination may be slower, as has also been reported for other basic compounds and Flecainide BNM dosage may need to be reduced.

**Renal impairment:** A reduced dosage in cases of severe renal impairment is recommended (see "Dosage and administration"). Haemodialysis is ineffective in removing unchanged flecainide from the body.

**Hepatic impairment:** Patients with significant hepatic impairment should not receive flecainide unless the potential benefits outweigh the risk. See "Dosage and administration" recommendations.

**Blood dyscrasias:** There have been extremely rare reports of blood dyscrasias (pancytopenia, anaemia, thrombocytopenia, leukopenia, granulocytopenia). Although no causal relationship has been established, it is advisable to discontinue Flecainide BNM in patients who develop blood dyscrasias in order to eliminate flecainide as the possible causative agent.

**Lung disease:** There have been very rare reports of lung disease (pulmonary fibrosis, interstitial lung disease and pneumonitis). Although no causal relationship has been established, it is advisable to discontinue Flecainide BNM in patients who develop lung disease in order to eliminate flecainide as the possible causative agent.

**Occupational hazards:** Since flecainide can cause dizziness, light-headedness, faintness and visual disturbance, patients should be cautioned about engaging in activities requiring judgement and physical coordination (such as driving an automobile or operating dangerous machinery) when these effects occur.

**Use in pregnancy:** (Category B3) Flecainide has been shown to have teratogenic effects (e.g. club paws, sternbral and vertebral abnormalities, pale hearts with contracted ventricular septa) and an embryotoxic effect (e.g. increased resorptions) in one breed of rabbit (New Zealand White) but not in another (Dutch Belted), when given in doses about four times (but not three times) the usual human dose (assuming a patient weight of 50 kg). No teratogenic effects were observed in rats or mice given doses up to 50 and 80 mg/kg/day, respectively, however, delayed sternbral and vertebral ossification was observed at the high dose in rats. Although the significance of these findings to humans is uncertain, since there is no information on the effect on the human foetus, Flecainide BNM should not be used during pregnancy unless as a drug of last resort in life-threatening arrhythmias.

**Labour and delivery:** It is not known whether the use of flecainide during labour or delivery has immediate or delayed adverse effects on the mother or foetus, affects the duration of labour or delivery or increases the possibility of forceps delivery or other obstetrical intervention.
Use in lactation: No specific studies are available to determine the excretion of flecainide in human breast milk. However, limited data indicate that flecainide is excreted in breast milk. The benefit of Flecainide BNM during lactation should therefore be weighed against possible effects on the child.

INTERACTIONS WITH OTHER MEDICINES

Alcohol
No information available.

Food
Food does not affect either the rate or extent of Flecainide BNM absorption.

Drugs
Digoxin: During multiple oral dosage of flecainide to healthy subjects stabilised on a maintenance dose of digoxin, a 13% ± 19% increase in plasma digoxin levels occurred at six hours post dose. These small changes in digoxin levels should be of no clinical consequence for patients receiving chronic digoxin therapy. Flecainide has been administered to patients receiving digitalis preparations without adverse effects.

β-adrenergic blocking agents: Flecainide has been administered to patients receiving β-adrenergic blocking agents without adverse effects. In a formal interaction study conducted in healthy males receiving flecainide and propranolol concurrently, plasma flecainide levels were about 20% higher and propranolol levels about 30% higher, in comparison to control values. These small changes should be of no clinical consequence. In this study, flecainide and propranolol were each found to have slight negative inotropic effects on cardiac function; when administered together these effects were never any more than additive. The effects of concomitant administration of flecainide and propranolol on the PR interval were less than additive. While these effects were of little clinical consequence in healthy subjects, the possibility of exaggerated effects from this combination in patients with reduced left ventricular function should be borne in mind. In flecainide clinical trials, patients who were receiving β-blockers concurrently did not experience an increased incidence of side effects. Nevertheless, the possibility of additive negative inotropic effects of β-blockers and flecainide should be recognised.

Anti-arrhythmics: See above, "Concomitant antiarrhythmic therapy".

Nifedipine, diltiazem: There has been too little experience with the co-administration of flecainide with nifedipine or diltiazem to recommend concomitant use.

Diuretics: Flecainide has been used in large numbers of patients receiving diuretics without apparent interactive effects.

Cimetidine: In healthy subjects receiving cimetidine (1 g daily) for one week, plasma flecainide levels increased by about 30% and half-life increased by about 10%.
Other drugs: Although formal interaction studies have not been conducted with flecainide and other drugs, flecainide is not extensively bound to plasma proteins and consequently interactions with other drugs which are highly protein bound (e.g. anticoagulants) would not be expected.

Limited data in patients receiving known enzyme inducers (phenytoin, phenobarbital, carbamazepine) indicate only a 30% increase in the rate of flecainide elimination.

ADVERSE EFFECTS

Flecainide has been evaluated in 1,224 patients participating in clinical trials which included both life threatening and non-life threatening ventricular arrhythmias. The most serious adverse reactions reported for flecainide in patients with ventricular arrhythmias were new or exacerbated ventricular arrhythmias which occurred in 6.8% of patients and new or worsened congestive heart failure which occurred in 3.9% of patients. In some patients, flecainide treatment has been associated with episodes of unresuscitatable ventricular tachycardia or ventricular fibrillation. There have also been instances of second- (0.5%) or third-degree (0.4%) AV block. A total of 1.2% of patients developed sinus bradycardia, sinus pause, or sinus arrest (see "Precautions"). The frequency of most of these serious adverse reactions probably increases with higher trough plasma levels, especially when these trough levels exceed 1.0 µg/mL.

The most commonly reported non-cardiac reactions experienced by patients with ventricular arrhythmias were dizziness 27%, visual disturbance 26% (includes blurred vision, diplopia, visual field effects, photophobia), headache 10%, nausea 10% and dyspnoea 9%.

Other adverse reactions occurring in over 3% of the patients in clinical trials:

- **Body as a Whole** - fatigue 7%, asthenia 5%;
- **Cardiovascular** - palpitations 6%, chest pain 6%;
- **Gastrointestinal** - constipation 4%, abdominal pain 3%;
- **Nervous System** - tremor 6%, nervousness 3%, paraesthesia 3%;
- **Skin** - rash 4%.

The following additional adverse reactions, possibly related to flecainide therapy and occurring in 1 to less than 3% of patients have been reported in clinical trials:

- **Body as a Whole** - pain, increased sweating, flushing, dry mouth, arthralgia, fever, myalgia;
- **Cardiovascular** - oedema, syncope, tachycardia, angina pectoris, conduction disturbance;
- **Gastrointestinal** - vomiting, diarrhoea, anorexia;
- **Nervous System** - hypoaesthesia, somnolence, insomnia, ataxia;
- **Respiratory** - coughing;
- **Skin** - pruritus;
- **Special Senses** - tinnitus;
- **Urinary System** - micturition disorder (includes urinary retention, frequency, polyuria, dysuria).
The following additional adverse experiences, possibly related to flecainide, have been reported in less than 1% of patients:

**Body as a Whole** - impotence, decreased libido, gynaecomastia, malaise;

**Cardiovascular** - bradycardia, EC abnormality, hypertension, hypotension, heart disorder, myocardial infarction, peripheral ischaemia, pulmonary oedema;

**Gastrointestinal** - dyspepsia, flatulence, GI haemorrhage;

**Nervous System** - anxiety, twitching, convulsions, nystagmus, stupor, dysphonia, speech disorder, coma, amnesia, confusion, depersonalisation, hallucination, paranoid reaction, euphoria, apathy;

**Respiratory** - bronchospasm, laryngismus;

**Skin** - dermatitis, hypertrichosis, photosensitivity reaction, skin discoloration;

**Special Senses** - deafness, parosmia, loss of taste, taste perversion;

**Urinary System** - renal failure, haematuria;

**Laboratory Abnormalities** - hyperglycaemia, increased nonprotein nitrogen, increased serum alkaline phosphatase, increased serum SGPT and SGOT. Patients with elevations of liver function tests have been asymptomatic and no cause and effect relationship with flecainide has been established.

Adverse reactions leading to discontinuation of therapy occurred in 18.5% of the patients. The two most common were non-cardiac adverse reactions 9.0% and new or worsened arrhythmias 6.8%.

Flecainide has been evaluated in 225 patients with supraventricular arrhythmias. The most serious adverse reactions reported for flecainide in patients with supraventricular arrhythmias were new or worsened supraventricular or ventricular arrhythmias which were reported in 4% of patients (see "Precautions"), conduction disturbance which occurred in 2% of patients and new or worsened congestive heart failure which occurred in 0.4% of patients.

The most commonly reported non-cardiac adverse reactions for supraventricular arrhythmia patients remain consistent with those known for patients treated with flecainide for ventricular arrhythmias: vision disturbance 38%, dizziness 37%, headache 18%, nausea 18%, dyspnoea 13%, fatigue 13%, chest pain 12%, palpitations 11%. Although these incidences are higher than those reported in ventricular arrhythmia patients it is difficult to compare supraventricular and ventricular data bases because many of the supraventricular arrhythmia patients were dosed to tolerance in the clinical trials.

In post-marketing surveillance experience, there have been rare reports of hepatic dysfunction including reports of cholestasis and hepatic failure, very rare reports of pulmonary fibrosis, interstitial lung disease and pneumonitis, and extremely rare reports of blood dyscrasias (see “Precautions”). Although no cause and effect relationship has been established, it is advisable to discontinue Flecainide BNM in these patients in order to eliminate flecainide as the possible causative agent.
DOSSAGE AND ADMINISTRATION

Adults
The dosage of Flecainide BNM must be adjusted to the individual needs of each patient based on therapeutic response and tolerance. The following regimen is suggested as a guideline. However dosage may need to be modified if the age, weight, or clinical status of the patient dictates.

When transferring patients who have been receiving another antiarrhythmic drug to Flecainide BNM, it is suggested that at least two plasma half-lives of the drug being discontinued should be allowed to elapse before starting Flecainide BNM at the usual dosage. In patients where withdrawal of a previous antiarrhythmic agent is likely to produce life-threatening arrhythmias, the physician should consider hospitalising the patient.

In patients with supraventricular arrhythmias, oral therapy may be started on an outpatient basis, however, in patients with sustained ventricular arrhythmias oral therapy should be initiated in hospital.

Flecainide has a long half-life (12 to 27 hours in patients). Steady-state plasma levels, in patients with normal renal and hepatic function may not be achieved until the patient has received 3 to 5 days of therapy at a given dose. Therefore, increases in dosage should be made no more frequently than once every four days, since during the first 2 to 3 days of therapy the optimal effect of a given dose may not be achieved.

For patients with supraventricular arrhythmias (PSVT and PAF), the recommended starting dose is 50 mg every 12 hours. Flecainide BNM doses may be increased in increments of 50 mg bid every four days until efficacy is achieved. For PAF patients, a substantial increase in efficacy without a substantial increase in discontinuations for adverse experiences may be achieved by increasing the Flecainide BNM dose from 50 to 100 mg bid. The maximum recommended dose for patients with paroxysmal supraventricular arrhythmias is 300 mg/day.

For sustained VT the recommended starting dose is 100 mg every 12 hours. This dose may be increased in increments of 50 mg bid every four days until efficacy is achieved. Most patients with sustained VT do not require more than 150 mg every 12 hours (300 mg/day) and the maximum dose recommended is 400 mg/day.

An occasional patient not adequately controlled by or intolerant to a dose given at 12-hourly intervals may be given Flecainide BNM at 8-hourly intervals.

Once adequate control of the arrhythmia has been achieved, the dosage may be reduced as necessary to reduce side effects or to minimise flecainide’s effects on conduction (see "Precautions"). A loading dose to achieve more rapid control of the arrhythmia is not recommended because of the possibility that the use of a loading dose may increase the likelihood of adverse effects. Flecainide BNM should be used cautiously in patients with a history of myocardial dysfunction or congestive heart failure.
In patients with severe renal impairment (creatinine clearance of 20 mL/min/m² or less), the initial dosage should be 100 mg once daily (or 50 mg bid); when used in such patients, frequent plasma level monitoring is required to guide dosage adjustments. In patients with less severe renal disease, the initial dosage should be 100 mg every 12 hours; plasma level monitoring may also be useful in these patients during dosage adjustment. In both groups of patients, dosage increases should be made very cautiously, observing the patient closely for signs of adverse cardiac effects or other toxicity. It should be borne in mind that in these patients it may take longer than four days before a new steady-state plasma level is reached following a dosage change.

In the presence of alkaline urine (pH greater than 7.0) dosage may need to be reduced (see “Precautions”).

Amiodarone:
As for many other anti-arrhythmic agents, in the presence of amiodarone, plasma levels of flecainide may be altered. Four situations may be encountered:

1. Flecainide BNM stopped and amiodarone started: Wait three plasma half-lives of flecainide (about 3 days) before starting amiodarone.

2. Flecainide BNM continued and amiodarone introduced. The dose of Flecainide BNM should be reduced to 50% at the same time as amiodarone is started. Plasma levels should be taken prior to and after amiodarone therapy is started. Based on therapeutic response and plasma levels, Flecainide BNM dosage can be adjusted accordingly. Avoid levels that exceed the therapeutic range of flecainide (0.2 to 1.0 μg/mL).

3. Amiodarone stopped and Flecainide BNM started: As the elimination of amiodarone is extremely slow, Flecainide BNM should be started at a dose of 50 mg bid. Plasma level monitoring of flecainide should be done frequently. Based on therapeutic response and plasma levels the dosage of Flecainide BNM can be adjusted accordingly.

4. Amiodarone continued and Flecainide BNM started: When adding Flecainide BNM to the regimen of a patient on a stabilised and well tolerated dose of amiodarone, Flecainide BNM should be started at a dose of 50 mg bid and plasma level monitoring of flecainide should be done frequently. Based on therapeutic response and plasma levels, the dosage of Flecainide BNM can be adjusted accordingly. Increases in Flecainide BNM dosage should be made carefully in increments not exceeding 50 mg bid and only after levels of flecainide have been obtained. If the dosage of amiodarone is changed, again carefully monitor plasma levels of flecainide and adjust Flecainide BNM dosage accordingly.

Paediatric use

Not recommended for use in children, as safety and efficacy have not been established.
Use in the elderly

The rate of flecainide elimination may be reduced in the elderly. An initial dose of 100 mg bid is recommended in otherwise healthy patients with cautious increases in dosage.

Patients with impaired liver function

As flecainide is extensively metabolised, presumably in the liver, patients with impaired liver function may require adjustment to dosage and should be carefully monitored. Efficacy studies revealed sporadic elevation of serum alkaline phosphatase and transaminases but no studies in liver impaired patients have been completed. Plasma flecainide should be monitored.

Patients with impaired renal function

In patients with severe renal impairment the dose of Flecainide BNM should be reduced (see adult dosage above). Plasma flecainide should be monitored.

Plasma level monitoring: The large majority of patients successfully treated with flecainide were found to have trough plasma flecainide levels varying between 200 to 1,000 ng/mL. The probability of cardiac adverse experiences may increase with higher trough plasma flecainide levels, especially when these exceed 1,000 ng/mL. Periodic monitoring of trough plasma flecainide levels may be helpful to show whether a patient has received an adequate dose to obtain a plasma flecainide level within the therapeutic range or whether a patient has exceeded this range. Because elimination of flecainide from plasma may be slower in patients with severe chronic renal failure or severe congestive heart failure, plasma flecainide level monitoring may be especially important in these patients.

OVERDOSAGE

For information on the management of overdose, contact the Poison Information Centre on 13 11 26 (Australia).

Clinical features: No data are available concerning overdosage of flecainide in humans. However, animal studies suggest the following events may occur: lengthening of the PR interval; increases in the QRS duration, QT interval and amplitude of the T-wave; a reduction in myocardial rate and contractility; conduction disturbances; hypotension; and death from respiratory failure or asystole.

Management: Treatment of overdose should be supportive and may include the following: administration of inotropic agents or cardiac stimulants such as dopamine, dobutamine or isoprenaline; mechanically assisted respiration; circulatory assistance such as intra-aortic balloon pumping and transvenous pacing in the event of conduction block. Because of the long plasma half-life of flecainide (range from 12 to 27 hours in patients), these supportive treatments may need to be continued for extended periods of time. Haemodialysis is not an effective means of removing flecainide from the body.
For the treatment of Flecainide BNM overdose when urine is clearly alkaline, acidification of urine (e.g. with ammonium chloride) may promote flecainide elimination. When urine is not clearly alkaline, it may be of some benefit to empirically acidify the urine in severe overdose cases.

PRESENTATION AND STORAGE CONDITIONS

50 mg Tablets: White, circular, biconvex, uncoated tablets embossed “C” on one face and the identifying letters “FI” on the reverse.

100 mg Tablets: White, circular, biconvex, uncoated tablets embossed with a breakline and the identifying letters “C” above the line and “FJ” below; the reverse embossed with a breakline.

Flecainide BNM is supplied in PVC/PVDC/Al blister packs in cardboard cartons. Each carton contains 60 tablets. Store below 25°C. Protect from light.

NAME AND ADDRESS OF THE SPONSOR

Boucher & Muir Pty Ltd
Level 1, 134 Willoughby Road
Crows Nest NSW 2065

POISON SCHEDULE OF THE MEDICINE

Schedule 4 - Prescription Only Medicine.

DATE OF FIRST INCLUSION IN THE AUSTRALIAN REGISTER OF THERAPEUTIC GOODS (ARTG)

20 November 2015

DATE OF MOST RECENT AMENDMENT

20112015